Rongdean Chen

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Jeffrey Crowley, Diamant Thaçi, P. Joly et al. · Journal of the American Academy of Dermatology · 2017 · 192 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)

Phoebe Rich, Melinda Gooderham, H. Bachelez et al. · Journal of the American Academy of Dermatology · 2015 · 165 citations · Full text

Medicine, Dermatology, Pharmacology +13

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

Robert Bissonnette, David M. Pariser, Norman Wasel et al. · Journal of the American Academy of Dermatology · 2016 · 83 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.

Linda Stein Gold, Jerry Bagel, Mark Lebwohl et al. · PubMed · 2018 · 59 citations

Medicine, Clinical Sciences, Pharmacotherapy +10

Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.

Bruce Strober, Jerry Bagel, Mark Lebwohl et al. · PubMed · 2017 · 55 citations

Medicine, Dermatology, Pharmacotherapy +11